{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+2&page=2", "query": { "condition": "Alzheimer Disease 2", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+2&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T03:44:40.406Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05637801", "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Alzheimer Disease 1", "Alzheimer Disease 2", "Alzheimer Disease 3", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Alzheimer Disease 9", "Alzheimer Disease 4", "Alzheimer Disease 7", "Alzheimer Disease 17", "Alzheimer's Dementia Late Onset", "Alzheimer Disease 5", "Alzheimer Disease 6", "Alzheimer Disease 8", "Alzheimer Disease 10", "Alzheimer Disease 11", "Alzheimer Disease 12", "Alzheimer Disease 13", "Alzheimer Disease 14", "Alzheimer Disease 15", "Alzheimer Disease 16", "Alzheimer Disease 18", "Alzheimer Disease 19", "Dementia", "Dementia Alzheimers", "Dementia, Mild", "Dementia of Alzheimer Type", "Dementia Moderate", "Dementia Senile", "Mild Cognitive Impairment", "Mild Dementia", "MCI", "Cognitive Impairment", "Cognitive Decline", "Cognitive Impairment, Mild" ], "interventions": [ { "name": "Spectris™ AD - Active", "type": "DEVICE" }, { "name": "Spectris™ AD - Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cognito Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 670, "start_date": "2022-12-13", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 68, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05637801" }, { "nct_id": "NCT07589595", "title": "A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Dysfunction", "Lewy Body Disease", "Synucleinopathies", "Amyloid" ], "interventions": [ { "name": "Donanemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 350, "start_date": "2026-05", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 42, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 37 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07589595" }, { "nct_id": "NCT00722046", "title": "Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "PF-04360365 0.1 mg/kg", "type": "BIOLOGICAL" }, { "name": "PF-04360365 0.5 mg/kg", "type": "BIOLOGICAL" }, { "name": "PF-04360365 1 mg/kg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04360365 3 mg/kg", "type": "BIOLOGICAL" }, { "name": "PF-04360365 8.5 mg/kg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 198, "start_date": "2008-12-05", "completion_date": "2011-08-16", "has_results": true, "last_update_posted_date": "2022-11-07", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 15, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Miami, Florida + 6 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722046" }, { "nct_id": "NCT02246075", "title": "Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease", "Dementia", "Cognition" ], "interventions": [ { "name": "EVP-6124", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "FORUM Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2015-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-15", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 2, "location_summary": "Delray Beach, Florida • Albuquerque, New Mexico", "locations": [ { "city": "Delray Beach", "state": "Florida" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02246075" }, { "nct_id": "NCT00208819", "title": "A Comparison of Two Standard Therapies in the Management of Dementia With Agitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Senile Dementia, Alzheimer Type", "Dementia, Alzheimer Type", "Alzheimer Disease", "Dementia" ], "interventions": [ { "name": "risperidone", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "divalproex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 50, "start_date": "2003-09", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2013-11-13", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00208819" }, { "nct_id": "NCT05847153", "title": "MASC: Reducing Stress for Caregivers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease and Related Dementias", "Dementia Alzheimers" ], "interventions": [ { "name": "MASC", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2023-09-12", "completion_date": "2024-01-13", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05847153" }, { "nct_id": "NCT02502253", "title": "BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mild Cognitive Impairment", "Alzheimer's Disease" ], "interventions": [ { "name": "grape seed polyphenolic extract, resveratrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 14, "start_date": "2015-06", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02502253" }, { "nct_id": "NCT00818662", "title": "A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer´s Disease" ], "interventions": [ { "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg", "type": "BIOLOGICAL" }, { "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg", "type": "BIOLOGICAL" }, { "name": "Placebo solution: Human Albumin 0.25% - 4 mL/kg", "type": "BIOLOGICAL" }, { "name": "Placebo solution: Human Albumin 0.25% - 2 mL/kg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 390, "start_date": "2008-12-19", "completion_date": "2012-12-10", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00818662" }, { "nct_id": "NCT04179721", "title": "Reducing Behavioral and Psychological Symptoms of Dementia: Hospital Caregivers (Aim 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer's Disease and Related Dementias" ], "interventions": [ { "name": "PES-4-BPSD Model", "type": "BEHAVIORAL" }, { "name": "The attention control condition", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2019-10-22", "completion_date": "2021-05-18", "has_results": true, "last_update_posted_date": "2022-11-03", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 2, "location_summary": "Glen Oaks, New York • Manhasset, New York", "locations": [ { "city": "Glen Oaks", "state": "New York" }, { "city": "Manhasset", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04179721" }, { "nct_id": "NCT05704309", "title": "The Diabetes Prevention Program Outcomes Study AD/ADRD Project", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes", "Alzheimer Disease", "Dementia, Vascular", "Dementia", "PreDiabetes" ], "interventions": [], "intervention_types": [], "sponsor": "Marinella Temprosa", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1976, "start_date": "2022-11-07", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-06-11T03:44:40.406Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Alhambra", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05704309" } ] }